Go to navigation Go to content
Toll-Free: 877-BRENT-ADAMS
Phone: (919) 781-7590
Brent Adams & Associates

Sepsis Drug Xigris Pulled From Shelves Worldwide Due to Ineffectiveness

Blog Category:
Brent Adams
Comments (0)
Ten years after it was approved by the Food & Drug Administration (FDA), the sepsis drug Xigris has been withdrawn from the market. Pharmaceutical company Eli Lilly has advised all hospitals to stop using the drug. A new study has found that the intravenous medicine is not effective and does not save patient lives.

Sepsis is an extremely serious medical condition in which a person's immune system overreacts to an infection, causing often-fatal organ failure. Xigris was introduced into the market in 2001 as a treatment for sepsis, despite some studies finding that the drug may cause dangerous amounts of bleeding.

Three years ago, the PROWESS-SHOCK study looked at almost 1,700 patients who had been treated for sepsis with Xigris. Although the study found that severe bleeding did not affect a significant number of patients, it also found that the fatality rate for patients taking Xigris was actually slightly higher than those given a placebo. After the study's completion, the drug company that manufactures the drug made the decision to stop production.

Sales of the drug were an estimated $100 million last year alone.

A defective drug isn't just a drug that causes harm - it is also a drug that lacks effectiveness. If you believe that your health has been affected by an ineffective prescription drug, speak to a North Carolina defective drug attorney today.

Category: Defective Drugs

There are no comments.

Post a comment

Post a Comment to "Sepsis Drug Xigris Pulled From Shelves Worldwide Due to Ineffectiveness"

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."


Email:* (will not be published)


Notify me of follow-up comments via email.